Suppes T
US Department of Veterans Affairs Palo Alto Health Care System, USA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: tsuppes@stanford.edu.
ArticlePsilocybin
Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression.
ArticlePsilocybin
Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial.
ArticlePsilocybin
Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.
ArticlePsilocybin
Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders.
ArticlePsilocybin
Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds.
ArticlePsilocybin
Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study.
ArticlePsilocybin
Psilocybin and hallucinogenic mushrooms - ERRATUM.
ArticlePsychedelics
Psychedelics for Depression: Between Hopes and Uncertainties.
ArticleMDMA
Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical Trial.
ArticlePsilocybin
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.
ArticlePsilocybin
Psilocybin and hallucinogenic mushrooms.
ArticlePsilocybin
Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.
ArticlePsilocybin